Literature DB >> 23585206

Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course.

Andrzej Lekstan, Marek Olakowski, Beata Jabłońska, Krzysztof Łabuzek, Edyta Olakowska, Ines Filip, Paweł Lampe.   

Abstract

UNLABELLED: Pancreatic cancer (PC) is the fourth leading cause of death in the world, due to neoplastic disease. Chronic pancreatitis (CP) is a progressive disease leading towards pancreatic fibrosis. The aim of the study was to assess the impact of matrix metalloproteinases 2 and 9 (MMP2 and 9) and their tissue inhibitor (TIMP 1 and 2) concentrations in case of PC and CP tissue homogenates on early treatment results of patients subject to pancreatic resections.
MATERIAL AND METHODS: The study group comprised 63 patients, including 25 (39.68%) female and 38 (60.32%) male patients. Group 1 (CP) consisted of 31 patients with CP (F: M = 10/21). Group 2 (PC) consisted of 32 patients with PC (F: M = 15:17). The pancreatic tumor samples were collected from the resected pancreas, being subject to electrophoresis and immunoenzymatic studies. After confirming their activity, MMP2, MMP9, TIMP1, TIMP2 concentrations were determined. Correlation analysis of MMPs and TIMPs concentrations was performed in relation to the following: tumor diameter, age, BMI, hospitalization, duration of symptoms and surgery, blood loss, incidence of perioperative complications.
RESULTS: Group differences were presented in terms of: age, BMI, ASA, duration of symptoms, jaundice, tumor diameter, time of operation. There were no differences considering weight loss, blood loss, extent of resection, and hospitalization. Significant MMPs and TIMPs concentration differences between groups were demonstrated.
CONCLUSIONS: Comparison of PC to CP tissue samples showed significantly higher levels of metalloproteinases and TIMPs in the former. Positive correlations of MMP1, TIMP1 and 2 with tumor diameter (CP) were observed, and MMP2 with the duration of surgery and blood loss (PC). There was no MMPs and TIMPs concentration levels influence on the incidence of postoperative complications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23585206     DOI: 10.2478/pjs-2013-0012

Source DB:  PubMed          Journal:  Pol Przegl Chir        ISSN: 0032-373X


  5 in total

Review 1.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

2.  Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.

Authors:  R Roy; D Zurakowski; J Wischhusen; C Frauenhoffer; S Hooshmand; M Kulke; M A Moses
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

3.  Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Authors:  Karoly Szepeshazi; Andrew V Schally; Norman L Block; Gabor Halmos; Mehrdad Nadji; Luca Szalontay; Irving Vidaurre; Andrew Abi-Chaker; Ferenc G Rick
Journal:  Oncotarget       Date:  2013-05

4.  Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC).

Authors:  Marta Łukaszewicz-Zając; Mariusz Gryko; Sara Pączek; Maciej Szmitkowski; Bogusław Kędra; Barbara Mroczko
Journal:  Oncotarget       Date:  2019-01-08

5.  GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 Pathway.

Authors:  Xu Ying; Li Jing; Shijie Ma; Qianjun Li; Xiaoling Luo; Zhenguo Pan; Yanling Feng; Pan Feng
Journal:  Cancer Cell Int       Date:  2015-07-05       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.